Table 1 Laboratory data
Case | Sex | Age | WBC | HGB | PLT | Disease stage | Clinical diagnosis | Outcome | Karyotype | RT-PCR | FISH |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | M | 47 | 298.3 | 83 | 603 | Initial diagnosis | CML | Recurrence at 9 months after CML diagnosis and imatinib treatment | 46,XY,t(9;22)(q34;q11.2)[15] | BCR/ABL positive, MLL/AF9 negative | Interphase: BCR/ABL positive, MLL/AF9 undetermined |
Post-recurrence | CML blastic phase AML-M2 | Died 4 months after recurrence of CML as AML-M2 and chemotherapy | 46,XY,der(9)t(9;22)(q34;q11.2)t(9;11)(p22;q23),der(11)t(9;11)(p22;q23),der(22)t(9;22)(q34;q11.2)[20] | BCR/ABL positive, MLL/AF9 positive | BCR/ABL positive, MLL/AF9 positive | ||||||
2 | F | 25 | 414.7 | 75 | 297 | Initial diagnosis | CML | Recurrence at 1 year after CML diagnosis and imatinib treatment | 46,XX,t(9;22)(q34;q11.2)[20] | BCR/ABL positive, MLL/AF9 negative | Interphase: BCR/ABL positive, MLL/AF9 undetermined |
Post-recurrence | CML blastic phase AML-M2 | Died 6 months after recurrence of CML as AML-M2 and chemotherapy | 47,XX,t(5;7)(q33;q21),der(9)t(9;22)(q34;q11.2)t(9;11)(p22;q23),der(11)t(9;11)(p22;q23),+21,der(22)t(9;22)(q34;q11.2)[20] | BCR/ABL positive, MLL/AF9 positive | BCR/ABL positive, MLL/AF9 positive | ||||||
3 | M | 41 | 150.02 | 123 | 82 | Initial diagnosis | AML-M5 | Died 6 months after AML diagnosis and treatment | 46,XY,t(9;22)(q34;q11.2),inv(16)(p13;q22)[17]/47,idem,+der(22)t(9;22)(q34;q11.2)[3] | BCR/ABL positive, CBFβ/MYH11 positive | BCR/ABL positive, CBFβ positive |
4 | M | 58 | 46 | 64 | 34 | Initial diagnosis | AML | Died 8 months after AML diagnosis and treatment | 46,XY,t(3;21)(q26;q22),t(9;22)(q34;q11.2)[20] | BCR/ABL positive, AML1-MDS/EVI1 positive | BCR/ABL positive, EVI1 positive |
5 | M | 46 | 113.52 | 88 | 554 | Initial diagnosis | CML | Recurrence at 4 months after CML diagnosis and oral imatinib treatment (treatment voluntarily discontinued at times) | 46,XY,t(9;22)(q34;q11.2)[15] | BCR/ABL positive, RUNX1-RUNX1T1 negative | Interphase: BCR/ABL positive, RUNX1-RUNX1T1 undetermined |
Post-recurrence | CML | Post-recurrence morphology and flow cytometry results indicated accelerated phase of CML. Died of internal organ bleeding 1 week after recurrence | 46,XY,t(9;22)(q34;q11.2)[10]/46,idem,t(8;21)(q22;q22)[10] | BCR/ABL positive, RUNX1-RUNX1T1 positive | BCR/ABL positive, RUNX1-RUNX1T1 positive |